JP2006063074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006063074A5 JP2006063074A5 JP2005219763A JP2005219763A JP2006063074A5 JP 2006063074 A5 JP2006063074 A5 JP 2006063074A5 JP 2005219763 A JP2005219763 A JP 2005219763A JP 2005219763 A JP2005219763 A JP 2005219763A JP 2006063074 A5 JP2006063074 A5 JP 2006063074A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- hydroxymethyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 62
- 239000008194 pharmaceutical composition Substances 0.000 claims 46
- 108090001061 Insulin Proteins 0.000 claims 31
- 102000004877 Insulin Human genes 0.000 claims 31
- 101700032406 IAA Proteins 0.000 claims 24
- 239000003392 amylase inhibitor Substances 0.000 claims 24
- 101700007658 leg3 Proteins 0.000 claims 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 239000003623 enhancer Substances 0.000 claims 12
- 230000002708 enhancing Effects 0.000 claims 12
- 230000035945 sensitivity Effects 0.000 claims 12
- WLDBVPWSCOUGQI-ZMMVPWHFSA-N (2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-4,5-dihydroxy-6-[(2R,3R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-3-yl]oxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](NC[C@H]2O)CO)O[C@@H]1CO WLDBVPWSCOUGQI-ZMMVPWHFSA-N 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 230000000580 secretagogue Effects 0.000 claims 10
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 9
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 8
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 8
- 101700062901 DPP Proteins 0.000 claims 7
- 102100012353 DPP4 Human genes 0.000 claims 7
- 101700039720 DPP4 Proteins 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 4
- 229960005095 Pioglitazone Drugs 0.000 claims 4
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- WLDBVPWSCOUGQI-WPCAJUIMSA-N (2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-4,5-dihydroxy-6-[(2R,3R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-3-yl]oxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](NC[C@H]2O)CO)O[C@@H]1CO WLDBVPWSCOUGQI-WPCAJUIMSA-N 0.000 claims 3
- 229960003105 Metformin Drugs 0.000 claims 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N Nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 3
- 229960000698 Nateglinide Drugs 0.000 claims 3
- MFFMDFFZMYYVKS-SECBINFHSA-N Sitagliptin Chemical group C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000003449 preventive Effects 0.000 claims 2
- 229960004586 rosiglitazone Drugs 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- QGJUIPDUBHWZPV-VFGQHSGRSA-N (1R,3S,5R)-2-[(2S)-2-amino-2-[(5S,7R)-3-hydroxy-1-adamantyl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile Chemical compound C([C@@H](C1)C2)[C@@H](C3)CC1(O)CC23[C@H](N)C(=O)N1[C@H](C#N)C[C@H]2C[C@H]21 QGJUIPDUBHWZPV-VFGQHSGRSA-N 0.000 claims 1
- SYOKIDBDQMKNDQ-HHUWHTLVSA-N (2S)-1-[2-[[(5S,7R)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C[C@H](C2)CC(C1)(C1)O)C21NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-HHUWHTLVSA-N 0.000 claims 1
- HBBJLDPBYHSWOK-ZMMVPWHFSA-N (2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-4,5-dihydroxy-6-[(2R,3R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-3-yl]oxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1NC[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 HBBJLDPBYHSWOK-ZMMVPWHFSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- -1 6-fluoro-6-deoxy-β-D-glucopyranosyl Chemical group 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N Buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229960004580 GLIBENCLAMIDE Drugs 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical group COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 1
- 206010020993 Hypoglycaemia Diseases 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 229960003243 Phenformin Drugs 0.000 claims 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N Phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N Rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 claims 1
- 229960004937 Saxagliptin Drugs 0.000 claims 1
- 108010026951 Short-Acting Insulin Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960004111 buformin Drugs 0.000 claims 1
- 229960004346 glimepiride Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000291 postprandial Effects 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 230000002829 reduced Effects 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005219763A JP2006063074A (ja) | 2004-07-29 | 2005-07-29 | 糖尿病治療薬を含有する医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004222419 | 2004-07-29 | ||
JP2005219763A JP2006063074A (ja) | 2004-07-29 | 2005-07-29 | 糖尿病治療薬を含有する医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006063074A JP2006063074A (ja) | 2006-03-09 |
JP2006063074A5 true JP2006063074A5 (fr) | 2008-09-04 |
Family
ID=36109854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005219763A Pending JP2006063074A (ja) | 2004-07-29 | 2005-07-29 | 糖尿病治療薬を含有する医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2006063074A (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3017536B1 (fr) * | 2014-02-18 | 2017-05-26 | Univ La Rochelle | Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02215394A (ja) * | 1989-02-14 | 1990-08-28 | Nippon Shinyaku Co Ltd | モラノリン誘導体の製法 |
JP2000044589A (ja) * | 1998-08-03 | 2000-02-15 | Kikkoman Corp | マルトオリゴ糖誘導体及びその用途 |
JP3909735B2 (ja) * | 1999-02-22 | 2007-04-25 | キッコーマン株式会社 | マルトオリゴ糖誘導体及びその用途 |
AU2001260695A1 (en) * | 2000-06-06 | 2001-12-17 | Kikkoman Corporation | Malto-oligosaccharide derivatives and use thereof |
-
2005
- 2005-07-29 JP JP2005219763A patent/JP2006063074A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101345316B1 (ko) | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 | |
KR101352588B1 (ko) | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 | |
US20200046713A1 (en) | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin | |
CN102596191B (zh) | 包含bi‑1356和二甲双胍的药物组合物 | |
CA2724133C (fr) | Preparation pharmaceutique comportant un inhibiteur de dpp-iv et autres agents therapeutiques du diabete sous forme concomitante ou combinee | |
KR102062824B1 (ko) | 2-[6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸]-4-플루오로-벤조니트릴의 용도 | |
CN109700814A (zh) | 对尽管使用口服或非口服抗糖尿病药物治疗但血糖控制仍不足的患者中的糖尿病的治疗 | |
JP2008007519A5 (fr) | ||
US20040209891A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
CN102971005A (zh) | 糖尿病治疗 | |
JP2010530431A5 (fr) | ||
CN102946875A (zh) | 组合疗法 | |
JP2016518438A (ja) | DPP−4阻害薬とα−グルコシダーゼ阻害薬との組合せ | |
KR20150038706A (ko) | 디펩티딜 펩티다아제 억제제의 주1회 투여 | |
JP2020529440A5 (fr) | ||
CA2575521A1 (fr) | Composition medicinale contenant un remede au diabete | |
JP2006063074A5 (fr) | ||
WO2009128360A1 (fr) | Agent thérapeutique pour le diabète | |
Agrawal et al. | Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin | |
TWI842924B (zh) | Gpr119致效劑及dpp-4抑制劑的藥物組合及藥物套組 | |
WO2011002011A1 (fr) | Agent thérapeutique combinant un inhibiteur de sglt1 et un inhibiteur de dpp-iv | |
RU2818562C2 (ru) | Комбинированная терапия агонистами gpr119 и ингибиторами dpp-4 | |
JPWO2011002012A1 (ja) | Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬 | |
JP4433496B2 (ja) | Atpクエン酸リアーゼの発現抑制用医薬組成物及びその使用 | |
JP2009513593A (ja) | 糖尿病の治療 |